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Abstract It is known that apoptosis may play a role in the
pathophysiology of amyotrophic lateral sclerosis (ALS).
Moreover, caspase-9 is implicated in the apoptosis path-
way. The aim of the study was to investigate caspase-9
levels in serum of patients with ALS. The study involved
30 patients with ALS and 30 patients from the control
group. The serum caspase-9 levels were measured using
the enzyme-linked immunosorbent method. The study
showed that caspase-9 levels are significantly increased in
serum of the patients with ALS comparing to the control
group (p \ 0.05). There was a significant correlation of
serum caspase-9 levels with severity of clinical state of
ALS patients and duration of the disease (p \ 0.05). The
results indicate that caspase-9 may be implicated in
pathomechanism of neurodegeneration in ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neu-
rodegenerative disease affecting motor neurons. Apoptosis
mediates programmed natural death of neurons and is a
physiologically important process in neurogenesis. How-
ever, premature apoptosis and/or an aberration in apoptosis
regulation may be implicated in the pathogenesis of neu-
rodegeneration in different neurological diseases, including
ALS [1]. Mitochondria play a key role in the apoptotic
process. Among the two of the signaling pathways of
apoptosis, i.e., the ‘‘extrinsic’’ and the ‘‘intrinsic’’ path-
ways, the latter is assumed to initiate in mitochondria. Its
activation involves the release of cytochrome c and other
pro-apoptotic factors from the mitochondrial intermem-
brane space. In the cytosol, cytochrome c binds to the
apoptosis protease activation factor (APAf-1) and forms a
complex indicated as ‘‘apoptosome.’’ The complex-
induced activation of pro-caspase-9 initiates an enzymatic
reaction cascade leading to the execution of apoptosis in
cells [2]. Caspase-9 is a member of caspase family of
cysteine proteases. Activated caspase-9 cleaves down-
stream caspases such as caspase-3, -6, and -7 initiating the
caspase cascade [3].
Data from the literature showed that apoptosis may play
a role in pathomechanism of ALS and degeneration of
motor neurons in this disease [4, 5]. Hetz et al. [6]
demonstrated that the proapoptotic Bcl-2 family member
Bcl-2-interacting mediator of cell death (BIM) mediates
motoneuron loss in a model of ALS. The apoptosis mark-
ers, including caspase-9, are activated in the ventral horn of
motor neurons in a transgenic mouse model of ALS [7, 8].
According to Gue´gan et al. [9] the mitochondrial-dependent
programmed cell death pathway, including the redistribution
of Bax, the cytosolic release of cytochrome c, and the
activation of caspase-9, is recruited during neurodegener-
ation in spinal cords of transgenic SOD1 mouse model of
ALS. It was also observed that the G93A mutant SOD1
interaction with DNA might induce DNA damage and
trigger the apoptotic response by activating p53. This toxic
activity of mutant SOD1 in the nucleus may play an
important role in the complex mechanisms associated with
motor neuron death observed in ALS pathogenesis [10].
The extracellular nucleotides mediate neuronal apoptosis
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via pathways involving C-jun N-terminal kinase 1 (JNK1),
extracellular signal-regulated kinase (ERK), and caspases
8/9/3 [11]. The balance between anti- and pro-apoptotic
proteins related to endoplasmic reticulum (ER) stress is
impaired from the pre-symptomatic stage in this ALS
mouse model, and this imbalance may be related to the
pathogenesis of motor neuron degeneration in ALS [12].
Inoue et al. [13] examined the effects of inhibition of X
chromosome-linked inhibitor of apoptosis (XIAP), a
mammalian inhibitor of caspase-3, -7, and -9. It was
observed that XIAP attenuated disease progression without
delaying onset. The authors suggest that caspase-9 plays a
crucial role in progression of ALS and constitutes a
promising therapeutic target. Thus, apoptosis contributes to
pathology in ALS, and appropriate anti-apoptosis therapy
might therefore be beneficial in this disease [14].
Although caspase-9 is an intracellular protein, it was
suggested that serum markers of apoptosis may be nonin-
vasive biomarkers in patients [15]. Moreover, data from the
literature shows that measurement of caspases in serum
could be useful in monitoring different diseases [16–19].
The aim of the study was to measure serum caspase-9
levels in patients with ALS and to investigate whether there
is a relationship of this caspase with clinical parameters of
the disease.
Materials and methods
Thirty ALS patients took part in the study. The ALS was
diagnosed according to the El Escorial criteria of ALS [20].
There were 23 patients with clinically definite ALS (the
presence of upper motor neuron as well as lower motor
neuron signs in the bulbar region and at least two spinal
regions, or the presence of upper motor neuron signs in two
spinal regions and lower motor neuron signs in three spinal
regions) and 7 patients with clinically probable ALS [upper
motor neuron and lower motor neuron signs in at least two
regions with some upper motor neuron signs rostral to
(above) the lower motor neuron signs] according to these
criteria. The clinical condition of the patients was mea-
sured by the revised version of Amyotrophic Lateral
Sclerosis Functional Rating Scale [ALSFRS-R] [21].
According to this scale the ALS patients scored from 0 to
39 points. They were divided into two subgroups: patients
with a mild clinical state (over 24 points according to
ALSFRS-R) and patients with a severe clinical state (up to
24 points according to ALSFRS-R). The patients with the
ALS were also divided according to the type of the disease
onset (patients with a limb-onset and patients with a bul-
bar-onset). The average duration of ALS was 16 months
(3 months–7 years). According to the duration of the dis-
ease, the two subgroups of patients were isolated (patients
with a short duration of ALS B12 months and patients with
a long duration of ALS [12 months). All patients with
ALS had nutritional deficiencies. The restriction of food
consumption, malnutrition, and weight loss was observed
because of progressive weakening of the muscles and
dysphagia.
The control group consisted of 30 patients with tension-
type headache. The patients from the control group were
recruited out of hospitalized patients and that is why
healthy persons were not included in the study. The
patients from control group were admitted to the hospital
because of acute headache occurred and it was necessary to
exclude subarachnoid hemorrhage. The characteristics of
patients are presented in Table 1.
The study was approved by the Ethics Committee of
Medical University and performed in accordance with the
ethical standards established in Helsinki.
Serum samples were collected into the plastic tubes,
centrifuged rapidly, and stored at -70C until the analysis
was performed. Caspase-9 levels were measured by the
enzyme-linked immunosorbent method using the commer-
cial ELISA kit for human Caspase-9 (Bender MedSystems,
Austria) in accordance with the manufacturer’s instructions.
The nonparametric Mann–Whitney rank sum test was used
to examine the differences between the groups because data
was not normally distributed. The correlation analysis was
performed using the Spearman rank correlation. The cas-
pase-9 values are expressed in ng/mL, as median and range.
P values\0.05 were considered significant.
Results
The study showed that the caspase-9 levels are significantly
increased in the serum of the whole group of patients with
ALS [5.4 (0.0–32.2) ng/mL] compared with those from the
control group [2.65 (0.0–14.3) ng/mL] (p \ 0.05). Cas-
pase-9 levels were still significantly increased in ALS
patients with long duration of the disease, with severe







Control 30 50 ± 7 15/15
ALS: total 30 54 ± 6 17/13
ALS: short duration 16 54 ± 3 9/7
ALS: long duration 14 54 ± 8 8/6
ALS: bulbar onset 12 60 ± 7 4/8
ALS: limb onset 18 50 ± 5 13/5
ALS: mild clinical state 14 49 ± 2 9/5
ALS: severe clinical state 16 57 ± 6 8/8
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clinical state, and with bulbar onset of ALS compared with
controls (p \ 0.05) but not in ALS patients with short
duration of the disease, with mild clinical state and with
limb onset of ALS compared with controls (p [ 0.05). The
difference in the serum caspase-9 levels between subgroups
of ALS patients according to the division of their type of
ALS onset, severity of clinical state, and duration of the
disease was not significant (p [ 0.05).
The median values of the serum caspase-9 levels, and a
comparative analysis between subgroups are presented in
Fig. 1 and in Table 2.
The correlation between serum caspase-9 and severity of
clinical state of ALS patients (ALSFRS-R score) and
duration of the disease was statistically significant
(r = 0.61, p = 0.01 and r = 0.48, p = 0.03; respectively).
There was no significant difference between of the age
of patients in ALS and controls (p = 0.47). There were
also no significant differences between the age of male and
female in patients with ALS and controls (p = 0.35 and
p = 0.28; respectively).
The difference of serum caspase-9 levels between ALS
male and female, and between younger (B55 years) and
older ([55 years) patients with ALS was not significant
(p = 0.61 and p = 0.14; respectively).
Discussion
There is evidence that apoptosis and activation of caspase-
9 play a role in different neurological diseases.
Darwish et al. [22] showed that activated caspase-9 and
cytochrome c are present in the cerebrospinal fluid (CSF)
of patients with severe traumatic brain injury.
Caspase-9 plays an important role in the development of
multiple sclerosis (MS). It was suggested that polymor-
phisms in the caspase-9 gene may influence the activity of
the disease [23].
According to Yu et al. [24], chronic extrinsic cervical
spinal cord compression leads to Fas-mediated apoptosis of
neurons and oligodendrocytes which is associated with
activation of caspase-8, -9, and -3 and progressive neuro-
logical deficits.
Spinal and bulbar muscular atrophy (SBMA) is a motor
neuron disease caused by polyglutamine expansion muta-
tion in the androgen receptor (AR). Ranganathan et al. [25]
showed that the mutant protein in MN-1 cells resulted in
increased Bax, caspase-9, and caspase-3.
The pilocarpine-induced status epilepticus (SE) results
in massive degenerative death of neuronal cells in brains.
The degenerating neurons, most of them also expressing
apoptosis signalling molecules such as caspase-9 and
activated caspase-3 [26].
Blandini et al. [27] measured the activity of proapoptotic
caspase-3 and -9 in peripheral blood lymphocytes (PBLs)
of Parkinson Disease (PD) and Alzheimer Disease (AD)
patients. Marked increases in caspase-3 and -9 activity
were found.
Presenilin 1 (PS1) gene mutations are the major causes
of early onset familial AD. Acceleration of apoptosis,
elevation of caspase-3/7 activity, and significant increases
in caspase-4, -8, and -9 activities during apoptosis induced
by several agents were found in the mutant PS1-transfected
cells [28].
It has been postulated that the pathogenesis of PD is
associated with mitochondrial dysfunction. Rotenone



























Fig. 1 Serum caspase-9 level in
patients with ALS and control
(p = 0.03)
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released cytochrome c into the cytosol, reduced cyto-
chrome c content in mitochondria, and reduced activation
of caspase-9 and -3 [29].
It was suggested that molecular targeting of the Apaf-1-
caspase-9 signalling pathway may be a feasible neuropro-
tective strategy to enhance the endogenous threshold for
caspase activation and prevent neuronal loss in stroke [30].
It was showed that acetaminophen reduces apoptosis (and
activation of caspase-9) in an in vivo model of cerebral
ischemia–reperfusion [31].
It was demonstrated that agents that improve mitochondrial
function or inhibit the permeability transition may eliminate
increased caspase -3 and -9 activation and cell death associ-
ated with enhanced N-methyl-D-aspartate receptor (NMDAR)
activity in Huntington’s disease (HD) [32].
It is known that sera from 26% of patients with sporadic
ALS induced in vitro apoptosis of a human neuroblastoma
cell line. In mixed cultures of rat embryonic brain and
spinal cord cells the sera from ALS patients induced the
apoptosis of a subpopulation of motoneurons [33]. It was
demonstrated that intrathecally infused TAT-fused protein
was effectively transferred into spinal cord neurons of ALS
transgenic mice, including motor neurons, and that intra-
thecal infusion of TAT-modified Bcl-X(L) delayed disease
onset, prolonged survival, and improved motor perfor-
mance. Histological studies show the attenuation of motor
neuron loss and decrease in the number of cleaved caspase
9-, cleaved caspase 3-, and terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL)-
positive cells in the lumbar cords of TAT-modified Bcl-
X(L)-treated G93A mice [34].
This study showed that the caspase-9 levels are signifi-
cantly increased in the serum of the whole group of patients
with ALS compared with those from the control group.
This indicates that caspase-9 is implicated in pathophysi-
ology of ALS. It may be interesting to know caspase-9
levels also in the cerebrospinal fluid of patients with ALS
but this measurement will be the subject of the next
research. Caspase-9 levels were significantly increased in
ALS patients with long duration of the disease, with severe
clinical state, and with bulbar onset of ALS compared with
controls but not in ALS patients with short duration of the
disease, with mild clinical state, and with limb onset of
ALS compared with controls. The correlation between
serum caspase-9 and severity of clinical state of ALS
patients, and the duration of the disease was statistically
significant. This indicates that apoptosis is more advanced
in patients with severe clinical state, bulbar onset, and a
long duration of the disease. Moreover, it is known that
patients with bulbar onset of ALS have more severe clin-
ical state than patients with limb onset of the disease.
Tokuda et al. [35] demonstrated that caspases are present in
nonactive forms in the spinal cords of wild-type mice
during the early stage of the disease. In transgenic mice, the
caspases are present in their active forms. During the
advanced stage of the disease, when paralysis is present,
the active caspases levels are increased. Data from the
recent study confirm this observation and suggest that
caspase-9 plays a role in pathophysiology of ALS, and anti-
apoptotic therapy might be helpful in this disease.
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